www.sperotherapeutics.com Open in urlscan Pro
34.249.200.254  Public Scan

Form analysis
2 forms found in the DOM

Name: wf-form-Email-Form---1-2 — GET

<form id="wf-form-Email-Form---1-2" name="wf-form-Email-Form---1-2" data-name="Email Form - 1" method="get" class="cta-form" data-wf-page-id="631a51447f7b0154dec9928a" data-wf-element-id="eb718516-c979-259c-3eca-ace38f74fc27"
  aria-label="Email Form - 1" data-hs-cf-bound="true">
  <div class="signup-form-wrapper"><input class="form-input w-input" aria-required="true" maxlength="256" name="email-4" data-name="Email 4" aria-label="email signup form-1" placeholder="Enter your email" type="email" id="email-4" required=""><input
      type="submit" data-wait="Please wait..." role="button" class="button is-small-dark-blue w-button" value="Stay Connected"></div>
</form>

Name: wf-form-Email-Form---2 — GET

<form id="wf-form-Email-Form---2" name="wf-form-Email-Form---2" data-name="Email Form - 2" method="get" class="signup-form_form" data-wf-page-id="631a51447f7b0154dec9928a" data-wf-element-id="0cd4b8c1-3f06-ed77-7495-f49cc10c0ec9"
  aria-label="Email Form - 2" data-hs-cf-bound="true">
  <h4 id="w-node-_0cd4b8c1-3f06-ed77-7495-f49cc10c0eca-c10c0eb7">Receive news and announcements in your inbox.</h4><input class="form-input w-node-_0cd4b8c1-3f06-ed77-7495-f49cc10c0ecc-c10c0eb7 w-input" aria-required="true" maxlength="256"
    name="email-6" data-name="Email 6" aria-label="email signup form-2" placeholder="Enter your email" role="input" type="email" id="email-6" required=""><input type="submit" data-wait="Please wait..." role="button"
    id="w-node-_0cd4b8c1-3f06-ed77-7495-f49cc10c0ecd-c10c0eb7" class="button is-small-dark-blue w-button" value="Sign Up">
</form>

Text Content

About SPERO
Our Mission & VisionBoard of DirectorsManagement TeamPartners
Pipeline
SPR720SPR206Tebipenem HBrPosters & Publications
PATIENTS
Nontuberculous Mycobacteria (NTM) InfectionsTreating Antibiotic
ResistanceExpanded Access
Careers
Current Job ListingsLife At SperoArticles & BlogsBenefits
Connect
Investor RelationsPress ReleasesEvents & PresentationsStock InformationSEC
FilingsContact Us
ABOUT SPERO
Our Mission & VisionBoard of DirectorsManagement TeamPartners
PIPELINE
Our PipelineSPR720SPR206Tebipenem HbrPosters & Publications
PATIENTS
Nontuberculous Mycobacteria (NTM) InfectionsTreating Antibiotic
ResistanceExpanded Access
CAREERS
Current Job ListingsLife At SperoArticles & BlogsBenefits
CONNECT
Investor RelationsPress ReleasesEvents & PresentationsStock InformationSEC
FilingsContact Us




INCUBATING HOPE FOR PATIENTS WITH RARE AND INFECTIOUS DISEASES

As a leader in the infectious disease field, Spero Therapeutics is highly
committed to advancing new therapies for patients with rare orphan diseases and
serious, multi-drug resistant bacterial infections in both hospital and
community settings.

Explore our treatments



SPR720

Oral antibiotic designed to treat Nontuberculous Mycobacterial Pulmonary
disease, a rare disease

SPR720 has potential to be the first approved novel oral agent for
nontuberculous mycobacterial (NTM), addressing a significant unmet need to
arrest infection and prevent the lung damage that infection causes. If approved,
the broad spectrum oral candidate may be applicable to both non-refractory and
refractory patients. Once daily dosing is supported by clinical and non-clinical
studies.

Learn More About SPR720

SPR206

SPR206 is an innovative, investigational intravenous (IV) direct-acting
antibiotic that has shown antibiotic activity against multi-drug resistant (MDR)
Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae,
Acinetobacter baumannii and Pseudomonas aeruginosa in preclinical studies.

LEARN MORE ABOUT SPR206

TEBIPENEM HBR

Our product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide) is
designed as an oral antibiotic for the treatment of complicated urinary tract
infection (cUTI) and acute pyelonephritis (AP) to help patients avoid
hospitalizations and/or transition patients home after IV therapy.

LEARN MORE ABOUT TEBIPENEM HBR




SOLUTIONS FOR NTM DISEASE AND MDR BACTERIAL INFECTIONS


Nontuberculous Mycobacterium (NTM) pulmonary disease is a growing global health
concern and a significant unmet medical need, due to a lack of new medications
being developed to combat these bacteria. Treatment failure is common for
patients with NTM. The absence of effective and well-tolerated drugs leaves
patients without options and increasingly desperate for solutions.


Learn more

Spero is answering the call with an audacious mission to find new answers and
new treatment approaches to combat rare diseases and MDR bacterial infections
for future generations.





PHYSICIANS VIDEO Q & A



The information contained in this video is not intended to be a substitute for
professional medical advice, diagnosis, or treatment. Always seek the advice of
your physician or other qualified health provider with any questions you may
have regarding a medical condition. Never disregard professional medical advice
or delay in seeking it because of something you have seen on this website.

PARTNERSHIPS

Spero Therapeutics is pursuing collaborations with partners for expertise and
funding support.

Partner with Us

INVESTOR RELATIONS

Stock information, SEC filings, corporate governance, IR resources and more.

Explore Resources

CAREERS

Collaborative. Exciting. Challenging. Stimulating. Committed. Find opportunities
to join our team.

Learn More


SIGN UP TO RECEIVE NEWS AND ANNOUNCEMENTS.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

RECENTLY PUBLISHED

PASTEUR Act Reintroduced

PATIENTS

Physicians Video Q & A

PIPELINE

Explore Spero's Pipeline

Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company
focused on identifying, developing, and commercializing novel treatments for
bacterial infections, including multi-drug resistant bacterial infections and
rare diseases.

RECEIVE NEWS AND ANNOUNCEMENTS IN YOUR INBOX.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
About SPERO
Our Mission & VisionBoard of DirectorsManagement TeamPartners
Pipeline
SPR720SPR206Tebipenem HBrPosters & Publications
PATIENTS
Nontuberculous Mycobacteria (NTM) InfectionsTreating Antibiotic
ResistanceExpanded Access
Careers
Current Job ListingsLife At SperoArticles & BlogsBenefits
Connect
Investor RelationsPress ReleasesEvents & PresentationsStock InformationSEC
FilingsContact Us
ABOUT SPERO
Our Mission & VisionBoard of DirectorsManagement TeamPartners
PIPELINE
Our PipelineSPR720SPR206Tebipenem HbrPosters and Publications
PATIENTS
Nontuberculous Mycobacteria (NTM) InfectionsTreating Antibiotic
ResistanceExpanded Access
CAREERS
Current Job ListingsLife At SperoArticles & BlogsBenefits
CONNECT
Investor RelationsPress ReleasesEvents & PublicationsStock InformationSEC
FilingsContact Us
© 2024 Spero Therapeutics. All rights reserved.
Privacy PolicyTerms of Use
Cookie Settings